Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies addressing significant global medical needs. Specializing in identifying and developing novel treatments for inflammatory diseases like kidney and lung diseases, Dimerix utilizes its innovative receptor technology to address significant global medical needs. Our flagship product, DMX-200, is currently in development for kidney diseases and respiratory complications associated with COVID-19, with three Phase 3 clinical programs underway. Dimerix has also initiated longer-term programs targeting Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).